Belvarafenib

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameBelvarafenib
Drug Alias NameRG-6185GDC-5573HM-95573
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB-raf V600E inhibitorsSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors
TargetsB-raf V600ESerine/threonine-protein kinase B-rafC-Raf kinase
Therapy Area/IndicationsSolid tumoursMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdF. Hoffmann-La Roche LtdGenentech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia